Twenty highly sensitized patients desensitized with IVIG + rituximabplasma exchange were enrolled and randomized 1:1 to receive plasma-derived human C1-INH ( 20 IU/kg/dose ) versus placebo intraoperatively , then twice weekly for 7 doses .